|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02181 MABPHARM-B
Nominal 
0.365 +0.030 (+8.955%) | 2024/06 - Interim RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Cash from / (used in) Operating Activities | -- | 57,392 | (56,885) | (199,470) | (147,231) |
| Net Cash from / (used in) Investing Activities | -- | (3,505) | (104,955) | (179,418) | 155,999 |
| Net Cash from / (used in) Financing Activities | -- | 85,597 | 112,262 | (17,781) | (80,478) |
| Increase / (Decrease) in Cash & Cash Equivalents | -- | 139,484 | (49,578) | (396,669) | (71,710) |
| Cash & Cash Equivalents at beginning of period | -- | 33,568 | 81,556 | 484,846 | 588,720 |
| Effect of Foreign Exchange Rate Changes | -- | 293 | 1,590 | (6,621) | (32,164) |
| Others | -- | 0 | 0 | 0 | 0 |
| Cash & Cash Equivalents at end of period | -- | 173,345 | 33,568 | 81,556 | 484,846 |
| Remarks: | Real time quote last updated: 05/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -97,569,000 |
| %Change | -2.430% |
| EPS / (LPS) | RMB -0.020 |
| NBV Per Share (¥) | RMB 0.028 |